Protein | Taxonomy | gefitinib (IC50) | chlorpromazine (IC50) |
Adenylate cyclase type 1 | Rattus norvegicus (Norway rat) | | 1.3 |
Spike glycoprotein | Betacoronavirus England 1 | | 9.51 |
Replicase polyprotein 1ab | Betacoronavirus England 1 | | 9.51 |
Solute carrier family 22 member 1 | Homo sapiens (human) | | 4.3 |
Transmembrane protease serine 2 | Homo sapiens (human) | | 9.51 |
Glutamate receptor ionotropic, NMDA 2D | Homo sapiens (human) | | 0.85 |
Glutamate receptor ionotropic, NMDA 3B | Homo sapiens (human) | | 0.85 |
Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | | 3.4 |
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | | 0.0052 |
Potassium channel subfamily K member 2 | Homo sapiens (human) | | 2.7 |
Tyrosine-protein kinase Fyn | Homo sapiens (human) | | 8.68 |
Procathepsin L | Homo sapiens (human) | | 9.51 |
Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | | 0.019 |
Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | | 0.652 |
Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | | 0.149 |
Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | | 0.025 |
Alpha-2A adrenergic receptor | Homo sapiens (human) | | 0.352 |
Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | | 9.51 |
Replicase polyprotein 1ab | Human coronavirus 229E | | 9.51 |
Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | | 9.51 |
Calmodulin-1 | Homo sapiens (human) | | 7.63 |
Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | | 9.51 |
Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | | 0.083 |
Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | | 5.8275 |
D(2) dopamine receptor | Homo sapiens (human) | | 0.0142 |
Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | | 0.031 |
Alpha-2B adrenergic receptor | Homo sapiens (human) | | 0.026 |
Alpha-2C adrenergic receptor | Homo sapiens (human) | | 0.374 |
D | Rattus norvegicus (Norway rat) | | 0.1414 |
D(3) dopamine receptor | Rattus norvegicus (Norway rat) | | 0.0416 |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | | 4.685 |
Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | | 1.4791 |
D(2) dopamine receptor | Bos taurus (cattle) | | 0.5328 |
Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | | 0.206 |
D(1A) dopamine receptor | Homo sapiens (human) | | 0.225 |
D(4) dopamine receptor | Homo sapiens (human) | | 1.365 |
Adenylate cyclase type 3 | Rattus norvegicus (Norway rat) | | 1.3 |
Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | | 1.4791 |
Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | | 1.4791 |
Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | | 0.031 |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | | 0.019 |
Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | | 1.4791 |
Histamine H2 receptor | Homo sapiens (human) | | 2.626 |
Alpha-1D adrenergic receptor | Homo sapiens (human) | | 0.004 |
D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | | 0.0416 |
Adenylate cyclase type 2 | Rattus norvegicus (Norway rat) | | 1.3 |
Adenylate cyclase type 4 | Rattus norvegicus (Norway rat) | | 1.3 |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | | 0.0036 |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | | 0.0052 |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | | 4.685 |
Trypanothione reductase | Trypanosoma cruzi | | 5.8 |
D(4) dopamine receptor | Rattus norvegicus (Norway rat) | | 0.0416 |
Sodium-dependent serotonin transporter | Homo sapiens (human) | | 0.0795 |
Melanocortin receptor 5 | Homo sapiens (human) | | 7.617 |
Pleiotropic ABC efflux transporter of multiple drugs | Saccharomyces cerevisiae S288C | | 4.5 |
Histamine H1 receptor | Homo sapiens (human) | | 0.0145 |
Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | | 1.3 |
D(3) dopamine receptor | Homo sapiens (human) | | 0.012 |
Sodium channel protein type 1 subunit alpha | Homo sapiens (human) | | 4.3 |
Sodium channel protein type 4 subunit alpha | Homo sapiens (human) | | 4.3 |
Adenylate cyclase type 8 | Rattus norvegicus (Norway rat) | | 1.3 |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | | 0.126 |
Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | | 0.031 |
5-hydroxytryptamine receptor 6 | Homo sapiens (human) | | 0.057 |
Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | | 9.51 |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | | 0.0365 |
Calmodulin | Bos taurus (cattle) | | 2.5 |
Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | | 1.3 |
Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | | 1.3 |
Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | | 1.3 |
Sodium channel protein type 7 subunit alpha | Homo sapiens (human) | | 4.3 |
Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | | 3.4 |
Sodium-dependent dopamine transporter | Homo sapiens (human) | | 2.643 |
Adenylate cyclase type 6 | Rattus norvegicus (Norway rat) | | 1.3 |
Adenylate cyclase type 5 | Rattus norvegicus (Norway rat) | | 1.3 |
Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | | 0.85 |
Aldehyde oxidase | Homo sapiens (human) | | 0.57 |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | | 1.9602 |
Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | | 0.85 |
Glutamate receptor ionotropic, NMDA 2B | Homo sapiens (human) | | 0.85 |
Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | | 3.4 |
Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | | 3.4 |
Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | | 4.3 |
Glutamate receptor ionotropic, NMDA 2C | Homo sapiens (human) | | 0.85 |
Sodium channel protein type 9 subunit alpha | Homo sapiens (human) | | 4.3 |
Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | | 1.3 |
Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | | 5.8275 |
Adenylyl cyclase 7 | Rattus norvegicus (Norway rat) | | 1.3 |
Glutamate receptor ionotropic, NMDA 3A | Homo sapiens (human) | | 0.85 |
Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | | 1.3 |
D | Bos taurus (cattle) | | 0.646 |
Sodium channel protein type 2 subunit alpha | Homo sapiens (human) | | 4.3 |
Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | | 0.451 |
Angiotensin-converting enzyme 2 | Homo sapiens (human) | | 9.51 |
Sodium channel protein type 3 subunit alpha | Homo sapiens (human) | | 4.3 |
Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | | 1.3 |
Sodium channel protein type 11 subunit alpha | Homo sapiens (human) | | 4.3 |
Sodium channel protein type 8 subunit alpha | Homo sapiens (human) | | 4.3 |
Sodium channel protein type 10 subunit alpha | Homo sapiens (human) | | 4.3 |
Authors | Studies |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Dalvie, D; Loi, CM; Smith, DA | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Espinoza, JL; Fujii, A; Fujimoto, K; Fujiwara, R; Hanamoto, H; Iwata, Y; Kumode, T; Matsumura, I; Morita, Y; Rai, S; Serizawa, K; Tanaka, H; Taniguchi, Y | 1 |
Article | Year |
Hologram QSAR model for the prediction of human oral bioavailability.Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).Journal of medicinal chemistry, 2008, Jun-12, Volume: 51, Issue:11
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, 2010, Volume: 23, Issue:1
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury. | 2010 |
Which metabolites circulate? | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells.Biochemical and biophysical research communications, 2022, 10-20, Volume: 626Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chlorpromazine; Drug Resistance, Neoplasm; ErbB Receptors; Everolimus; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |